Biochemical pharmacology and resistance to 2-chloro-2'-arabinofluoro-2'- deoxyadenosine, a novel analogue of cladribine in human leukemic cells

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2438-2444

  Lotfi, Kourosh ^a   Månsson, Emma ^b   Spasokoukotskaja, Tatjana ^c   Pettersson, Birgitta ^a   Liliemark, Jan ^b   Peterson, Curt ^a   Eriksson, Staffan ^d   Albertioni, Freidoun ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; DEOXYCYTIDINE KINASE; NUCLEOSIDE ANALOG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL STRAIN HL 60; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOPROLIFERATIVE DISEASE; MICHAELIS CONSTANT; MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLADRIBINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, T-CELL; PHOSPHORYLATION; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0345466497     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cheson, B. D. New antimetabolites in the treatment of human malignancies. Semin. Oncol., 19: 695-706, 1992.
2. Beutler, E., and Carson, D. A. 2-Chlorodeoxyadenosine: hairy cell leukemia takes a surprising turn. Blood Cells, 19: 569-572, 1993.
3. Piro, L. D., Ellison, D. J., and Saven, A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk. Lymphoma, 14: 121-125, 1994.
4. Piro, L. D., Carrera, C. J., Beutler, E., and Carson. D. A. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood, 72: 1069-1073, 1988.
5. Juliusson, G., and Liliemark, J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol., 11: 679-689, 1993.
6. Piro, L. D. Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Semin. Hematol., 33: 34-39, 1996.
7. Santana, V. M., Mirro, J., Jr., Kearns, C., Schell, M. J., Crom, W., and Blakley, R. L. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin. Oncol., 10: 364-370, 1992.
8. Vahdat, L., Wong, E. T., Wile, M. J., Rosenblum, M., Foley, K. M., and Warrell, R. P., Jr. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood, 84: 3429-3434, 1994.
9. Beutler, E., Sipe, J. C., Romine, J. S., Koziol, J. A., McMillan, R., and Zyroff, J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. USA, 93: 1716-1720, 1996.
10. Schirmer, M., Mur, E., Pfeiffer, K. P., Thaler, J., and Konwalinka, G. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand. J. Rheumatol., 26: 376-379, 1997.
11. Liliemark, J., Albertioni, F., Hassan, M., and Juliusson, G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol., 10: 1514-1518, 1992.
12. Carson, D. A., Wasson, D. B., and Beutler, E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. USA, 81: 2232-2236, 1984.
13. Albertioni, F., Pettersson, B., Reichelova, V., Juliusson, G., and Liliemark, J. Analysis of 2-chloro-2′-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. Ther. Drug Monit., 16: 413-418, 1994.
14. Albertioni, F., Hassan, M., Silberring, J., and Liliemark, J. Kinetics and metabolism of 2-chloro-2′-deoxyadenosine and 2-chloro-2′- arabino-fluoro-2′-deoxyadenosine in the isolated perfused rat liver. Eur. J. Drug Metab. Pharmacokinet., 20: 225-232, 1995.
15. Parker, W., Shaddix, Chang, C., White, L., Rose, L., Brockman, R., Shortnacy, A., Montgomery, J., Secrist, J., and Bennett, L. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 51: 2386-2394, 1991.
16. Xie, C., and Plunkett, W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res., 55: 2847-2852, 1995.
17. Xie, K. C., and Plunkett, W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl)adenine. Cancer Res., 56: 3030-3037, 1996.
18. Sjoberg, A. H., Wang, L., and Eriksson, S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol. Pharmacol., 53: 270-273, 1998.
19. Qian, M., Wang, X., Shanmuganathan, K., Chu, C. K., and Gallo, J. M. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine in rats. Cancer Chemother. Pharmacol., 33: 484-488, 1994.
20. Carson, D. A., Wasson, D. B., Esparza, L. M., Carrera, C. J., Kipps, T. J., and Cottam, H. B. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. USA, 89: 2970-2974, 1992.
21. Takahashi, T., Kanazawa, J., Akinaga, S., Tamaoki, T., and Okabe, M. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother. Pharmacol., 43: 233-240, 1999.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
23. Reichelova, V., Albertioni, F., and Liliemark, J. Determination of 2-chloro-2β-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl., 682: 115-123, 1996.
24. Spasokoukotskaja, T., Arner, E. S., Brosjo, O., Gunven, P., Juliusson, G., Liliemark, J., and Eriksson, S. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur. J. Cancer, 2: 202-208, 1995.
25. Usova, E., and Eriksson, S. Effects of high salt concentrations on the regulation of the substrate specificity of human recombinant deoxycytidine kinase. Eur. J. Biochem., 248: 762-766, 1997.
26. Wang, L., Karlsson, A., Arner, E. S., and Eriksson, S. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J. Biol. Chem., 268: 22847-22852, 1993.
27. Hatzis, P., Al-Madhoon, A. S., Jullig, M., Petrakis, T. G., Eriksson, S., and Talianidis, I. The intracellular localization of deoxycytidine kinase. J. Biol. Chem., 273: 30239-30243, 1998.
28. Lowry, U., Rosenbrough, N., Farr, A., and Randall, R. Protein measurement with folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
29. Johansson, M., Brismar, S., and Karlsson, A. Human deoxycytidine kinase is located in the cell nucleus. Proc. Natl. Acad. Sci. USA, 94: 11941-11945, 1997.
30. Reichelova, V., Liliemark, J., and Albertioni, F. Liquid chromatographic study of acid stability of 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, 2-chloro-2′-deoxyadenosine and related analogues. J. Pharm. Biomed. Anal., 13: 711-714, 1995.
31. Lindemalm, S., Liliemark, J., Larsson, B. S., and Albertioni, F. Distribution of 2-chloro-2′-deoxyadenosine, 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, fludarabine and cytarabine in mice. A wholebody autoradiography study. Med. Oncol., 16: 1-6, 1999.